| pubmed-article:6121761 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6121761 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:6121761 | lifeskim:mentions | umls-concept:C0007226 | lld:lifeskim |
| pubmed-article:6121761 | lifeskim:mentions | umls-concept:C0002962 | lld:lifeskim |
| pubmed-article:6121761 | lifeskim:mentions | umls-concept:C0020538 | lld:lifeskim |
| pubmed-article:6121761 | lifeskim:mentions | umls-concept:C1263846 | lld:lifeskim |
| pubmed-article:6121761 | lifeskim:mentions | umls-concept:C0035203 | lld:lifeskim |
| pubmed-article:6121761 | lifeskim:mentions | umls-concept:C0020259 | lld:lifeskim |
| pubmed-article:6121761 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:6121761 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:6121761 | lifeskim:mentions | umls-concept:C0332206 | lld:lifeskim |
| pubmed-article:6121761 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:6121761 | pubmed:dateCreated | 1982-6-21 | lld:pubmed |
| pubmed-article:6121761 | pubmed:abstractText | The effect of the beta-receptor blocking drug Tobanum was examined in 10 patients with idiopathic hyperkinetic heart syndrome. The circulation (arm-to-ear) time was determined by indicator-dilution method following methylene blue injection. The appearance, concentration, and dilution time was prolonged in each case 120 min after a single dose of 2.5 mg Tobanum. The heart rate decreased significantly. The hypotensive effect of Tobanum has been evaluated in 10 patients. A 2-week "wash-out" period preceded 5 weeks of adaptive dose administration (7.5-45 mg), and 2 weeks of placebo concluded the study. Both systolic and diastolic pressure and heart rate decreased during treatment with the drug. However, a significant increase again thereafter was observed in both standing and lying positions. The number of anginal attacks, amount of nitroglycerin consumption and the "angina index" decreased significantly in 5 of 10 patients with stable angina during the active treatment period (3 X 2.5 mg daily). Only in 1 case of 10 bronchitis patients and 10 healthy persons was a deterioration of vital capacity and FEV1 values found after a single dose of 2.5 mg Tobanum. | lld:pubmed |
| pubmed-article:6121761 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6121761 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6121761 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6121761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6121761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6121761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6121761 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6121761 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:6121761 | pubmed:issn | 0174-4879 | lld:pubmed |
| pubmed-article:6121761 | pubmed:author | pubmed-author:BükyPP | lld:pubmed |
| pubmed-article:6121761 | pubmed:author | pubmed-author:SzámII | lld:pubmed |
| pubmed-article:6121761 | pubmed:author | pubmed-author:GulyásAA | lld:pubmed |
| pubmed-article:6121761 | pubmed:author | pubmed-author:SinkovicsMM | lld:pubmed |
| pubmed-article:6121761 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6121761 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:6121761 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6121761 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6121761 | pubmed:pagination | 128-33 | lld:pubmed |
| pubmed-article:6121761 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:meshHeading | pubmed-meshheading:6121761-... | lld:pubmed |
| pubmed-article:6121761 | pubmed:year | 1982 | lld:pubmed |
| pubmed-article:6121761 | pubmed:articleTitle | Studies on a new beta-receptor blocking drug, tobanum--1-(2,5-dichlorophenoxy)-3-tertiary-butylamino-2-propanol HCl: its use in cardiovascular hyperkinetic syndrome, hypertension, and angina pectoris, and its effect on respiration. | lld:pubmed |
| pubmed-article:6121761 | pubmed:publicationType | Journal Article | lld:pubmed |
